Establishment and Application of a Method for Screening the Therapeutic Drugs of Ethanol-Induced Liver Injury Based on Cellular Metabonomics.

A drug-screening method to test the capacity of drugs to protect against ethanolinduced liver injury based on cellular metabonomics was established and applied in this study. It screens for the ability to protect against ethanol-induced liver injury by considering changes in the cellular metabolites of human normal liver L-02 cells subjected to ethanol treatment. This method considers cellular metabolites as the main analytical index, principal component analysis and orthogonal partial least squares discriminant analysis as the main multi-and megavariate data analysis methods, and vitamin C as the standard substance to determine the ability to protect against ethanol-induced liver injury. Ability to protect against ethanol-induced liver injury unit = [190 - 50x (14.318 - 10 x Y predictive value)(1/2)] x ability 1 mu g/mL vitamin C. Olive leaf extract, Lycium barbarum L extract and fish roe peptide were screened using the established methods. Olive leaf OP phase had the strongest ability to protect against ethanolinduced liver injury, at 81.88. The value for L. barbarum L was 37.56. The fish roe peptide water phase was 63.07. All three have the ability to protect against ethanolinduced liver injury. The drug-screening method for ability to protect against ethanol-induced liver injury based on cell metabonomics is a fast, accurate and effective method for quantitative detection of ability to protect against ethanol-induced liver injury.